Novel pharmacotherapy of acute hereditary angioedema with bradykinin B 2-receptor antagonist icatibant

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 61, Issue 12, 2006, Pages 1490-1492

  Bas, M ^a   Bier, H ^b   Greve, J ^b   Kojda, G ^b   Hoffmann, T K ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b NONE

Author keywords

Angioedema; Angiotensin converting enzyme inhibitor; Bradykinin B 2 receptor antagonist; C1 esterase inhibitor deficiency; Icatibant

Indexed keywords

BRADYKININ B2 RECEPTOR ANTAGONIST; ICATIBANT; PLASMIN; TRANEXAMIC ACID;

ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; DRUG TOLERABILITY; ERYTHEMA; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INJECTION SITE IRRITATION; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN BURNING SENSATION; SYMPTOMATOLOGY;

ACUTE DISEASE; ANGIONEUROTIC EDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; HUMANS; MIDDLE AGED; RECEPTOR, BRADYKININ B2;

EID: 33750526677     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2006.01197.x     Document Type: Article

References (4)

1. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998;351:1693-1697.
2. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992;71:206-215.
3. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005;139:379-394.
4. Icatibant: HOE 140, JE 049, JE049. Drugs R D 2005;6:239-244.